CD19 and congenital rubella syndrome: Drug-based strategies to mitigate severe inflammatory events like cytokine release syndrome (CRS) and associated neurotoxicity appeared initially in the setting of anti-CD19 CAR-T therapies (n= 7 including one CD19/CD20 dual receptor trial).